Fenofibrate

Administration
  • Type: Antihyperlipidemic
  • Dosage Forms:
  • Routes of Administration: oral
  • Common Trade Names:

Adult Dosing
  • 40-160mg PO daily

Pediatric Dosing

Safety/efficacy not established

Special Populations
  • Pregnancy Rating: C
  • Lactation risk: infant risk has been demonstrated
  • Renal dosing: contraindicated in severe impairement
  • Hepatic dosing: contraindicated in active liver disease, primary biliary cirrhosis, or unexplained persistent liver function abnormalities

Contraindications
  • Allergy to class/drug
  • Active liver or gallbladder disease
  • Severe renal impairment
  • Nursing mothers

Adverse Reactions

Serious
  • Pancreatitis
  • Cholestatic hepatitis
  • Rhabdomyolysis
  • Raised serum creatinine

Common
  • Abdominal pain, nausea
  • Abnormal LFTs
  • Backache
  • Rhinitis

Pharmacology
  • Half-life: 10-30h
  • Metabolism:
  • Excretion: Mostly renal

Mechanism of Action
  • Increases lipolysis and elimination of triglyceride-rich particles from plasma via activation of peroxisome proliferator-activated receptor alpha

Comments


See Also

References
    This article is issued from Wikem. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.